Impact News +++ AST SpaceMobile Prices Repurchase of Convertible Notes and Registered Direct Offering of Class A Common... (Business Wire) +++ AST SPACEMOBILE Aktie -3,48%

KEYMED Aktie

>KEYMED Aktienkurs

5.425 EUR (Tradegate)

Ask: 5.55 EUR / 538 Stück

Bid: 5.3 EUR / 571 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 8 bis 22 Uhr!

KEYMED Aktie über LYNX handeln

Intraday

1 Jahr

>KEYMED Performance

1 Woche: +8,7%

1 Monat: +18,9%

3 Monate: +18,7%

6 Monate: +36,8%

1 Jahr: +31,1%

laufendes Jahr: +47,7%

>KEYMED Aktie

Name:

KEYMED BIOSCIENCES -,0001

Land:

China

Sektor:

Gesundheit

ISIN/ Wkn:

KYG5252B1023 / A3CTJD

Symbol/ Ticker:

64Z (Frankfurt)

Kürzel:

FRA:64Z, ETR:64Z, 64Z:GR

Index:

Webseite:

https://www.keymedbio.com..

Marktkapitalisierung:

1550 Mio. EUR

Umsatz:

371.03 Mio. EUR

EBITDA:

-477.58 Mio. EUR

Gewinn je Aktie:

-0.208 EUR

Schulden:

652.79 Mio. EUR

Liquide Mittel:

1871.95 Mio. EUR

Umsatz-/ Gewinnwachstum:

1% / -

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

28.11 / 5.12 / -

Gewinnm./ Eigenkapitalr.:

-120.35% / -18.85%

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

KEYMED

Letzte Datenerhebung:

25.06.25

>KEYMED Eigentümer

Aktien: 275.6 Mio. St.

f.h. Aktien: 184.35 Mio. St.

Insider Eigner: 32.62%

Instit. Eigner: 30.83%

Leerverk. Aktien: -

>KEYMED Peer Group

3SBIO

ABBISKO

HBM HOLDINGS

HYGEIA

PARANOVUS

PEIJIA MEDICAL

SHANGHAI HAOHAI

SHANGHAI PHARMACEUTICALS

TONG REN TANG

VIVA BIOTECH

>KEYMED Chart & Kurs - Tradegate

>KEYMED News

13.06.25 - 11:06	Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine (PR Newswire)
	CHENGDU, China, June 12, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced that Prof. Jun Shi's research team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical......

11.06.25 - 04:45	KEYMED BIO-B Places Shrs at 6.5% Discount to Raise HKD850M+ Net Proceeds; Controlling Shareholder Cuts Stake (AAStocks)
	KEYMED BIO-B (02162.HK) has announced a share placement where Bo CHEN, the company's major shareholder, executive director, and CEO, placed 21.6 million existing shares at HKD45.48 per share (around 7.72% of the issued share capital), marking a discount of about 6.52% to yesterday's (10th) closing price.At the same time,......

25.04.25 - 05:54	Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers (PR Newswire)
	CHENGDU, China, April 25, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") recently announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational New Drug (IND) approval from the Center for Drug......

06.04.25 - 04:15	The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine (PR Newswire)
	CHENGDU, China, April 5, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its independently developed IL-4Rα antibody......

05.04.25 - 16:18	The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine (PR Newswire)
	CHENGDU, China, April 5, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its independently developed IL-4Rα antibody......

02.04.25 - 10:15	Full-day Takeaway: HSI Closes at 23,202, Down 4 pts; HSTI Closes at 5,426, Up 19 pts; CHOW TAI FOOK Up over 10%; WH GROUP, LEAPMOTOR, KEYMED BIO-B, CZBANK, CQRC BANK Hit New Highs; Market Turnover Rises (AAStocks)
	At close, HSI dropped 4 pts or 0.0% to 23,202. HSTI rose 19 pts or 0.4% to 5,426. HSCEI fell 5 pts or 0.1% to 8,531. Market turnover reached $216.60 billion.Active Heavyweights:HKEX (00388.HK) closed at $353.8, up 1.7%CCB (00939.HK) closed at $6.93, up 0.3%BABA (09988.HK) closed at $130, up 0.2%MEITUAN (03690.HK) closed at $157.......

02.04.25 - 06:15	Midday Takeaway: HSI Closes Midday at 23,221, Up 14 pts; HSTI Closes Midday at 5,438, Up 31 pts; CHOW TAI FOOK Up over 5%; LEAPMOTOR, CHINA EAST EDU, CQRC BANK, CZBANK, KEYMED BIO-B Hit New Highs (AAStocks)
	At midday close, HSI rose 14 pts or 0.1% to 23,221. HSTI rose 31 pts or 0.6% to 5,438. HSCEI gained 1 pts or 0.0% to 8,538.Active Heavyweights:HKEX (00388.HK) closed at $351.8, up 1.1%MEITUAN (03690.HK) closed at $157.7, down 0.1%TENCENT (00700.HK) closed at $503.5, down 0.1%BABA (09988.HK) closed at $129.9, up 0.1%HSI & HSCEI C......

26.03.25 - 16:12	Keymed Biosciences Announces Annual Results of 2024 (PR Newswire)
	CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate update. Rapid development of our pipeline products Stapokibart (CM310) (IL-4Rα antibody) Three new drug applications of......

10.01.25 - 02:30	Timberlyne Therapeutics Launches with a $180 Million Series A Financing to Advance CM313, a Potentially Best-in-Class Anti-CD38 Monoclonal Antibody, for Diseases of High Unmet Medical Needs (PR Newswire)
	Mountainfield Venture Partners, a biopharmaceutical company creation firm, partners with Keymed Biosciences to form Timberlyne Therapeutics, accessing global development and commercial rights outside of greater China for CM313 Financing co-led by Abingworth, Bain Capital Life Sciences,......

23.12.24 - 15:48	Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis (PR Newswire)
	CHENGDU, China, Dec. 23, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of Stapokibart (anti-IL-4Rα monoclonal antibody,......

13.09.24 - 14:14	China NMPA approves Keymed Biosciences′ Stapokibart for atopic dermatitis (PBR)
	This approval is based on results from a multicentre, randomised, double-blind, placebo-controlled Phase III trial. The study's co-primary endpoints were achieving a minimum of a 75% improvement in The post China NMPA approves Keymed Biosciences' Stapokibart for atopic dermatitis appeared first on Pharmaceutical Business review....

28.08.24 - 08:19	Keymed Biosciences Announces Interim Results for First Half of 2024 (PR Newswire)
	CHENGDU, China, Aug. 28, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced its interim results for the first half of 2024, along with a corporate update. Rapid development of our pipeline products Stapokibart (CM310) (IL-4Rα antibody) In June 2024, the long-term......

27.08.24 - 15:13	Keymed Biosciences Announces Interim Results for First Half of 2024 (PR Newswire)
	CHENGDU, China , Aug. 27, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced its interim results for the first half of 2024, along with a corporate update. Rapid development of our pipeline products Stapokibart (CM310) (IL-4Rα antibody) In June 2024, the long-term......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer das Recht mit Füßen tritt, steht selten fest auf den Beinen. - Stanislaw Jerzy Lec

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram